Multiple Myeloma Hub

The Multiple Myeloma Hub spoke with Fredrik Schjesvold, Oslo University Hospital, Oslo, NO. We asked how belantamab mafodotin is currently used in clinical practice for multiple myeloma (MM). In this interview, Schjesvold discusses the current use of belantamab mafodotin-based combinations in early relapsed/refractory MM, including their positioning alongside other available treatment options, suc...

The Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, DE. We asked, How are ocular toxicities associated with belantamab mafodotin managed in MM? In this interview, Einsele discusses the proposed mechanism of belantamab mafodotin-associated ocular toxicity, strategies for monitoring ocular changes, and the role of dose modifications in managing...

The Multiple Myeloma Hub was pleased to speak with Adam Cohen, University of Pennsylvania, Philadelphia, US. We asked about the rationale for targeting FcRH5 in multiple myeloma and emerging dual-targeting strategies. In this interview, Cohen discusses Fc receptor-homolog 5 (FcRH5) as a therapeutic target in multiple myeloma (MM) and its potential role following antigen loss associated with B-cell...

During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the long-term outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) in Cohort A of the CARTITUDE-2 trial. In t...

During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about interim results from Arm D of the UKMRA ProMMise trial in patients with relapsed/refractory multiple myeloma (RRMM). In this interview, Popat discusses interim results from Ar...

The Multiple Myeloma Hub spoke with Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK. We asked how to optimize outpatient delivery of bispecific antibody therapy for multiple myeloma (MM). In this interview, Popat discusses practical strategies to support the outpatient delivery of bispecific antibody therapy, including patient selection, caregiver support, and access to timely medical...

The Multiple Myeloma Hub spoke with Christoph Renner, University of Basel, Basel, CH. We asked about the use of belantamab mafodotin-based combination therapy for relapsed/refractory multiple myeloma (RRMM). During this interview, Renner provides an overview of pivotal clinical data from the DREAMM-7 and DREAMM-8 trials that supported regulatory approvals of belantamab mafodotin-based combinations...

The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma (MM) in community practice. In this interview, Mateos discusses practical considerations for the management of adverse events (AEs) associated with bispecific antibodies in MM. Mateos outlines h...

The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy. In this interview, Kumar discusses practical considerations for transitioning bispecific antibody therapy to community-based practice in patients with multiple myeloma. Kumar outlines strategies for monitoring and managing treatment-rela...

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM. The first analysis explored outcomes among patients who received only one prior LoT, while the second...

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical College of Wisconsin, Milwaukee, US. We asked, What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM? This educational resource is independently supported by Caribou Biosciences. All content is developed by SE...

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatme...

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges o...

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? This educational resource is independently supported by GSK. All content is developed by SES in collaboratio...

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improv...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the emerging role of cereblon E3 ligase modulators (CELMoDs) in newly diagnosed multiple myeloma (NDMM) and high-risk smoldering multiple myeloma. During this interview, Richardson discusses the use of CELMoDs, particularly iberdomide, in earlier lines of therapy. Richardson reviews clinic...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about cereblon E3 ligase modulators (CELMoDs) for the treatment of relapsed/refractory multiple myeloma (RRMM). During this interview, Richardson reviews clinical data on the activity of CELMoDs, including mezigdomide and iberdomide, in RRMM. Richardson highlights response rates observed in ongo...

The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory activity of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma. During this interview, Richardson discusses how CELMoDs target the cereblon E3 ubiquitin ligase complex to induce selective protein degradation and immunomodulatory effects...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat chaired a panel discussion featuring patient representative Lynn Williams, alongside faculty members Fredrik Schjesvold and Hang Quach, on real-world experience with belantamab mafodotin in mult...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU, delivered a presentation on optimizing dosing strategies for B-cell maturation antigen (BCMA)-directed therapies in mul...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). During this presentation, Schjesvold provides an...

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat, University College Hospital, London, UK, delivered a presentation on quality-of-life (QoL) considerations with B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, the panel, chaired by Hermann Einsele, discussed the practical considerations when sequencing novel agents and managing adverse events with B-cell maturation antigen (BCMA)-directed therapies in...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Maria Victoria Mateos provided an overview of the potential future directions with novel and established B-cell maturation antigen (BCMA)-directed therapies in the multiple myeloma (MM) treatment...

On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies into clinical practice: Insights from real-world experience. During the symposium, Gordon Cook, University of Leeds, UK, delivered a presentation covering real-world insights and clinical experience with BCMA-directed therapies. In this presentation,...